Targovax granted European Patent for mutant-RAS neoantigen platform lead products
Extends IP protection of TG01 and TG02 until 06.05.2034 Oslo, 17 January 2019: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the European Patent Office has granted European Patent no 3040320. The patent protects Targovax' mutant-RAS specific neoantigen peptides, mutant RAS specific T cells and vaccines TG01 and TG02, for the treatment of cancer in combination with chemotherapies.Jon Amund Eriksen, special advisor and Co-founder of Targovax, said: "We are delighted that